Advanced search×

The comparative efficacy of stabilized stannous fluoride/sodium hexametaphosphate dentifrice and sodium fluoride/triclosan/copolymer dentifrice for the control of gingivitis: a 6-month randomized clinical study.

Luis L Archila, Robert D RD Bartizek, J Leslie JL Winston, Aaron R AR Biesbrock, Stephen F SF McClanahan, and Tao T He

J Periodontol 75(12):1592-9 (2004) PMID 15732859

Antimicrobial agents such as stannous fluoride and triclosan have been incorporated into dentifrice formulations and have been shown to be effective in reducing gingivitis. The objective of this study was to compare the anti-gingivitis efficacy of a 0.454% stannous fluoride/sodium hexametaphosphate dentifrice to a positive control triclosan/copolymer dentifrice.

Version: za2963e q8za9 q8zbf q8zcd q8zdb q8zee q8zf9 q8zgb
Buy PDF

Similar articles you may find interesting…

  1. Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4).
    Yuichi Tamura, Tomohiko Ono, and Shigetake Sasayama

    Adv Ther (2013) PMID 23653230

    Switching from epoprostenol GM to the same dose of epoprostenol AS was well tolerated over 12 weeks of treatment, and pulmonary hemodynamics were maintained. Switching to epoprostenol AS was also associated with improvements in treatment satisfaction (convenience). Clinical Trials: JapicCTI-122017....
    Buy PDF
  2. Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Tri...
    Alexander C Ford and Laurent Peyrin-Biroulet

    Am J Gastroenterol (2013) PMID 23649185

    Anti-TNF therapy doubles the risk of opportunistic infections in inflammatory bowel disease patients. This underlines the importance of adherence to guidelines for their prevention and management.Am J Gastroenterol advance online publication, 7 May 2013; doi:10.1038/ajg.2013.138....
    Buy PDF
  3. The cost effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
    Anthony J Batty, Ryan N Hansen, and Sean D Sullivan

    J Med Econ (2013) PMID 23647483

    At 2 years, treatment with onabotulinumtoxinA was associated with an increase in costs of £1,367 and an increase in QALYs of 0.1 compared to placebo, resulting in an incremental cost-effectiveness ratio (ICER) of £15,028. Treatment with onabotulinumtoxinA reduced headache days by an estimated 38 d...
    Buy PDF